STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-015-1503-7
Published Online: 2015-07-04
Published Print: 2015-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Chibaudel, Benoist
Bonnetain, Franck
Tournigand, Christophe
de Larauze, Marine Hug
de Gramont, Armand
Laurent-Puig, Pierre
Paget, Jérôme
Hadengue, Alexandra
Notelet, Dominique
Benetkiewicz, Magdalena
André, Thierry
de Gramont, Aimery
License valid from 2015-07-04